A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.
You may also be interested in...
Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary
SHANGHAI - Months after pledging a policy change, China is finally taking steps to break ties between indigenous innovation and government procurement policies. The changes in policy, according to a report released by the U.S.-China Business Council, address growing concern among multinationals that procurement policies - an estimated $1 trillion market - are increasingly designed to shut them out
Insider Analysis From Morrison & Foerster LLP: China’s Bolar Exemption - Beware of the Uncertainties of Its Reach And Scope (Part 1 of 2)
By Janet Xiao, Morrison & Foerster LLP, Palo Alto and Michael Vella, Morrison & Foerster LLP, Shangha
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.